Ensysce Biosciences to Present Novel TAAPTM and MPARTM Opioid Technology at SMi 19th Annual Pain Therapeutics Conference May 14, 2019

Ensysce is leading the challenge of entering the opioid space when the political and regulatory climate is looking for new answers for analgesia. Opioid products are necessary for many indications, and Ensysce is providing an option for both patients and prescribers that can reduce abuse and stem overdose from these prescription products. The TAAP^TM oral prodrug technology and MPAR^TM overdose protection, both unique to the industry, have already demonstrated exceptional clinical results, received Fast Track Status from the FDA and are quickly moving through clinical development. Ensysce MPAR^TM platform has also received financial support from the National Institutes on Drug Abuse.

About Ensysce Biosciences

Ensysce is a clinical phase drug development company with a focus on prodrug compositions to overcome abuse, especially for the highly abused opioid and ADHD prescription drugs. As prescriptions for opioids have risen sharply over the last two decades, rates of addiction and overdose deaths have dramatically increased. Drug overdose deaths are now the leading cause of accidental death in the U.S. Abuse Deterrent Formulation (ADF) opioids have not stemmed this epidemic. Ensysce’s TAAP^TM and MPAR^TM products will change that and provide a promise of halting opioid deaths. Ensysce’s TAAP^TM/MPAR^TM platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug prodrug compositions. www.ensysce.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190510005272/en/